Rockwell Medical (RMTI) Upgraded by BidaskClub to Hold
BidaskClub upgraded shares of Rockwell Medical (NASDAQ:RMTI) from a sell rating to a hold rating in a research note released on Saturday morning.
Separately, Zacks Investment Research downgraded Rockwell Medical from a hold rating to a sell rating in a report on Thursday, January 4th.
Rockwell Medical (NASDAQ:RMTI) opened at $5.80 on Friday. Rockwell Medical has a fifty-two week low of $5.06 and a fifty-two week high of $8.98. The stock has a market capitalization of $311.70, a price-to-earnings ratio of -13.49 and a beta of 2.02.
Several large investors have recently made changes to their positions in RMTI. Athos Capital Ltd purchased a new position in shares of Rockwell Medical in the 3rd quarter valued at $6,834,000. Vanguard Group Inc. grew its stake in Rockwell Medical by 4.6% during the 2nd quarter. Vanguard Group Inc. now owns 2,080,843 shares of the company’s stock worth $16,501,000 after buying an additional 90,786 shares during the last quarter. State Street Corp grew its stake in Rockwell Medical by 7.4% during the 2nd quarter. State Street Corp now owns 903,142 shares of the company’s stock worth $7,160,000 after buying an additional 62,094 shares during the last quarter. GSA Capital Partners LLP grew its stake in Rockwell Medical by 216.8% during the 2nd quarter. GSA Capital Partners LLP now owns 76,566 shares of the company’s stock worth $607,000 after buying an additional 52,400 shares during the last quarter. Finally, Northern Trust Corp grew its stake in Rockwell Medical by 4.8% during the 2nd quarter. Northern Trust Corp now owns 618,045 shares of the company’s stock worth $4,901,000 after buying an additional 28,482 shares during the last quarter. Institutional investors and hedge funds own 21.26% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/01/10/rockwell-medical-rmti-upgraded-by-bidaskclub-to-hold.html.
About Rockwell Medical
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Stock Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related stocks with our FREE daily email newsletter.